Hepatitis B

Infectious Disease Clinics of North America

Volumn 14, Issue 3, 2000, Pages 617-632

  Befeler, Alex S ^b   Di Bisceglie, Adrian M ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; FAMCICLOVIR; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS DNA;

CHRONIC HEPATITIS; DISEASE CARRIER; ERADICATION THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; NONHUMAN; PREVALENCE; REVIEW; RISK FACTOR; SEROLOGY; UNITED STATES;

EID: 0033831396     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70124-0     Document Type: Article

References (76)

1. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection
2. Prevention of hepatitis B flare-up during chemotherapy using lamivudine: Case report and review of the literature
3. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal
4. Clinical significance of YMDD mutant hepatitis B virus in a large cohort of lamivudine treated hepatitis B patients
5. Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy
6. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation
7. Epidemiology of hepatocellular carcinoma
8. Multivariate analysis of prognostic factors in fulminant hepatitis B
9. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B
10. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen
11. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP)
12. Centers for Disease Control and Prevention: Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination; recommendations of the Immunization Practices Advisory Committee
13. Centers for Disease Control and Prevention: Recommendation of the Immunization Practices Advisory Committee: Inactivated hepatitis B virus vaccine
14. Centers for Disease Control and Prevention: Maternal hepatitis B screening practices: California, Connecticut, Kansas, and United States, 1992-1993
15. Centers for Disease Control and Prevention: Public health service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B
16. Incidence of hepatitis B virus infection in the United States, 1976-1994: Estimates from the National Health and Nutrition Examination Surveys
17. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa
18. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B
19. NLH conference. Hepatocellular carcinoma
20. Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B
21. Lamivudine as initial treatment for chronic hepatitis B in the United States
22. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee
23. Cellular immunity and hepatitis-associated, Australia antigen liver disease
24. Sample design: Third National Health and Nutrition Examination Survey
25. Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B
26. Natural history and prognostic factors for chronic hepatitis type B
27. Delayed clearance of serum HBsAg in compensated cirrhosis B: Relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP)
28. Hepatitis B virus infection among children born in the United States to Southeast Asian refugees
29. In vitro evaluation of potential add-on therapeutics for treatment of lamivudine treated patients with YMDD mutant HBV
30. Interactions between HIV and hepatitis B virus in homosexual men: Effects on the natural history of infection
31. Hepatitis B: Diagnosis, prevention, and treatment
32. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients
33. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure
34. Resolution of recurrent hepatitis B in two liver transplant recipients treated with famciclovir
35. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: Two placebo-controlled phase II studies
36. The treatment of chronic viral hepatitis
37. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B
38. Interactions between human immunodeficiency virus-1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus
39. Hepatitis A virus and hepatitis B virus vaccination in patients with chronic liver disease
40. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study
41. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa
42. Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation
43. Molecular virology and pathogenesis of hepatitis B
44. Medical progress. Acute liver failure
45. Medical progress: Hepatitis B virus infection
46. Clinical safety profile of lamivudine treatment in a large cohort of hepatitis B patients
47. Two-year lamivudine therapy in chronic hepatitis B infection: Results of a placebo controlled multi-centre study in Asia
48. Current therapeutic trends in therapy for chronic viral hepatitis
49. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
50. Treatment of chronic hepatitis B infection
51. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa
52. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon
53. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers
54. Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state
55. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: Results of a pilot study
56. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
57. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir
58. Predictors of HBeAg seroconversion in chronic hepatitis B patients treated with lamivudine
59. Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen
60. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group
61. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance
62. Biology of human hepatitis viruses
63. Therapy with nucleoside analogues for hepatitis B infection
64. Successful treatment of hepatitis B virus-associated polyarteritis nodosa by interferon alpha alone
65. HBeAg and anti-HBe detection by radioimmunoassay: Correlation with vertical transmission of hepatitis B virus in Taiwan
66. Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization
67. Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus
68. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation
69. Efficacy of famciclovir in chronic hepatitis B: Results of a dose finding study
70. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B
71. Extrahepatic manifestations of chronic viral hepatitis
72. Interferon alfa treatment of chronic hepatitis B: Randomized trial in a predominantly homosexual male population
73. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B
74. Hepatitis B virus and apparent fulminant non-A, non-B hepatitis
75. Human hepatitis B virus DNA polymerases which contain mutations arising during famciclovir treatment remain sensitive to adefovir
76. Alpha-interferon for chronic active hepatitis B in human immunodeficiency virus-infected patients